Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study

Parkinsonism and Related Disorders

Volumn 21, Issue 12, 2015, Pages 1427-1434

  Brockmann, Kathrin ^a,b   Schulte, Claudia ^a,b   Deuschle, Christian ^a,b   Hauser, Ann Kathrin ^a,b   Heger, Tanja ^a,b   Gasser, Thomas ^a,b   Maetzler, Walter ^a,b   Berg, Daniela ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Abeta; CSF; GBA; LRRK2; Parkinson; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; LEVODOPA; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; GLUCOSYLCERAMIDASE; LRRK2 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; FEMALE; GBA GENE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; LONGITUDINAL STUDY; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NERVE DEGENERATION; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; ANALYSIS; CEREBROSPINAL FLUID; CHEMISTRY; COGNITION DISORDERS; COMPARATIVE STUDY; FOLLOW UP; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTEIN PROCESSING; PSYCHOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS;

ADULT; AGED; AMYLOID BETA-PEPTIDES; BIOMARKERS; CEREBROSPINAL FLUID PROTEINS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHENOTYPE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TAU PROTEINS;

EID: 84955726381     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.10.008     Document Type: Article

References (36)

1. Aarsland D., Andersen K., Larsen J.P., Perry R., Wentzel-Larsen T., Lolk A., Kragh-Sorensen P. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 2004, 61:1906-1911.
2. Halliday G.M., Holton J.L., Revesz T., Dickson D.W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011, 122:187-204.
3. Halliday G., Hely M., Reid W., Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008, 115:409-415.
4. Compta Y., Parkkinen L., O'Sullivan S.S., Vandrovcova J., Holton J.L., Collins C., Lashley T., Kallis C., Williams D.R., de Silva R., Lees A.J., Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain J. Neurol. 2011, 134:1493-1505.
5. Alves G., Bronnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., Kurz M.W., Andreasson U., Tysnes O.B., Larsen J.P., Mulugeta E. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol., Neurosurg. Psychiatry 2010, 81:1080-1086.
6. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., Chung K.A., Kim H., Galasko D.R., Jankovic J., Zabetian C.P., Leverenz J.B., Zhang J. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25:2682-2685.
7. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
8. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
9. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., Waligorska T., Taylor P., Pan S., Frasier M., Marek K., Kieburtz K., Jennings D., Simuni T., Tanner C.M., Singleton A., Toga A.W., Chowdhury S., Mollenhauer B., Trojanowski J.Q., Shaw L.M. Parkinson's progression markers I. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013, 70:1277-1287.
10. Alves G., Lange J., Blennow K., Zetterberg H., Andreasson U., Forland M.G., Tysnes O.B., Larsen J.P., Pedersen K.F. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 2014, 82:1784-1790.
11. Parnetti L., Chiasserini D., Persichetti E., Eusebi P., Varghese S., Qureshi M.M., Dardis A., Deganuto M., De Carlo C., Castrioto A., Balducci C., Paciotti S., Tambasco N., Bembi B., Bonanni L., Onofrj M., Rossi A., Beccari T., El-Agnaf O., Calabresi P. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2014, 29:1019-1027.
12. Brockmann K., Groger A., Di Santo A., Liepelt I., Schulte C., Klose U., Maetzler W., Hauser A.K., Hilker R., Gomez-Mancilla B., Berg D., Gasser T. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov. Disord. Off. J. Mov. Disord. Soc. 2011, 26:2335-2342.
13. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M., Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
14. Nalls M.A., Duran R., Lopez G., Kurzawa-Akanbi M., McKeith I.G., Chinnery P.F., Morris C.M., Theuns J., Crosiers D., Cras P., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Mann D.M., Snowden J., Pickering-Brown S., Halliwell N., Davidson Y., Gibbons L., Harris J., Sheerin U.M., Bras J., Hardy J., Clark L., Marder K., Honig L.S., Berg D., Maetzler W., Brockmann K., Gasser T., Novellino F., Quattrone A., Annesi G., De Marco E.V., Rogaeva E., Masellis M., Black S.E., Bilbao J.M., Foroud T., Ghetti B., Nichols W.C., Pankratz N., Halliday G., Lesage S., Klebe S., Durr A., Duyckaerts C., Brice A., Giasson B.I., Trojanowski J.Q., Hurtig H.I., Tayebi N., Landazabal C., Knight M.A., Keller M., Singleton A.B., Wolfsberg T.G., Sidransky E. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013, 70:727-735.
15. Brockmann K., Srulijes K., Hauser A.K., Schulte C., Csoti I., Gasser T., Berg D. GBA-associated PD presents with nonmotor characteristics. Neurology 2011, 77:276-280.
16. Brockmann K., Srulijes K., Pflederer S., Hauser A.K., Schulte C., Maetzler W., Gasser T., Berg D. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. Off. J. Mov. Disord. Soc. 2015, 30:407-411.
17. Maetzler W., Karam M., Berger M.F., Heger T., Maetzler C., Ruediger H., Bronzova J., Lobo P.P., Ferreira J.J., Ziemssen T., Berg D. Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. J. Neural Transm. 2015, 122(3):419-425.
18. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., Quinn N., Sethi K.D., Shults C., Wenning G.K. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 2003, 18:467-486.
19. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., Poewe W., Sampaio C., Stern M.B., Dodel R., Dubois B., Holloway R., Jankovic J., Kulisevsky J., Lang A.E., Lees A., Leurgans S., LeWitt P.A., Nyenhuis D., Olanow C.W., Rascol O., Schrag A., Teresi J.A., van Hilten J.J., LaPelle N., Movement Disorder Society URTF Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. Off. J. Mov. Disord. Soc. 2008, 23:2129-2170.
20. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., Giladi N., Holloway R.G., Moore C.G., Wenning G.K., Yahr M.D., Seidl L., Movement Disorder Society Task Force on Rating Scales for Parkinson's D Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. Off. J. Mov. Disord. Soc. 2004, 19:1020-1028.
21. Hoops S., Nazem S., Siderowf A.D., Duda J.E., Xie S.X., Stern M.B., Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009, 73:1738-1745.
22. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
23. van Steenoven I., Aarsland D., Hurtig H., Chen-Plotkin A., Duda J.E., Rick J., Chahine L.M., Dahodwala N., Trojanowski J.Q., Roalf D.R., Moberg P.J., Weintraub D. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2014, 29:1809-1815.
24. Maetzler W., Schmid S.P., Wurster I., Liepelt I., Gaenslen A., Gasser T., Berg D. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov. Disord. Off. J. Mov. Disord. Soc. 2011, 26:176-181.
25. Hall S., Surova Y., Ohrfelt A., Zetterberg H., Lindqvist D., Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology 2015, 84:57-63.
26. Chiaravalloti A., Stefani A., Fiorentini A., Lacanfora A., Stanzione P., Schillaci O. Do CSF levels of t-Tau, p-Tau and beta(1)(-)(4)(2) amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A (1)(2)(3)I-FP-CIT study in the early stages of the disease. Eur. J. Nucl. Med. Mol. Imaging 2014, 41:2137-2143.
27. Aasly J.O., Shi M., Sossi V., Stewart T., Johansen K.K., Wszolek Z.K., Uitti R.J., Hasegawa K., Yokoyama T., Zabetian C.P., Kim H.M., Leverenz J.B., Ginghina C., Armaly J., Edwards K.L., Snapinn K.W., Stoessl A.J., Zhang J. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012, 78:55-61.
28. Arima K., Hirai S., Sunohara N., Aoto K., Izumiyama Y., Ueda K., Ikeda K., Kawai M. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res. 1999, 843:53-61.
29. Guo J.L., Covell D.J., Daniels J.P., Iba M., Stieber A., Zhang B., Riddle D.M., Kwong L.K., Xu Y., Trojanowski J.Q., Lee V.M. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013, 154:103-117.
30. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Kruger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
31. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B., Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain J. Neurol. 2009, 132:1783-1794.
32. Sardi S.P., Clarke J., Viel C., Chan M., Tamsett T.J., Treleaven C.M., Bu J., Sweet L., Passini M.A., Dodge J.C., Yu W.H., Sidman R.L., Cheng S.H., Shihabuddin L.S. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3537-3542.
33. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
34. Liu C., Cholerton B., Shi M., Ginghina C., Cain K.C., Auinger P., Parkinson Study Group DI, Zhang J. CSF tau and tau/Abeta42 predict cognitive decline in Parkinson's disease. Park. Relat. Disord. 2015, 21:271-276.
35. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., Shaw L.M., Van Deerlin V., Trojanowski J.Q., Clark C. CSF amyloid [beta] 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
36. Saman S., Kim W., Raya M., Visnick Y., Miro S., Saman S., Jackson B., McKee A.C., Alvarez V.E., Lee N.C., Hall G.F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 2012, 287:3842-3849.